Cargando…
A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus
BACKGROUND: The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556404/ https://www.ncbi.nlm.nih.gov/pubmed/34714420 http://dx.doi.org/10.1186/s43141-021-00262-8 |
_version_ | 1784592168253390848 |
---|---|
author | Omran, Mohamed M. Mosaad, Sara Emran, Tarek M. Eltaweel, Fathy M. Farid, Khaled |
author_facet | Omran, Mohamed M. Mosaad, Sara Emran, Tarek M. Eltaweel, Fathy M. Farid, Khaled |
author_sort | Omran, Mohamed M. |
collection | PubMed |
description | BACKGROUND: The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. This work aimed to assess interleukin (IL-6) and insulin-like growth factor 2 (IGF 2) as possible HCC markers in comparison to AFP in patients with and without HCC. RESULTS: ROC analysis showed that IGF2 had the highest area under the curve (AUC) for discriminating HCC from liver cirrhosis (0.86), followed by IL6 (0.82), AFP (0.72), and platelet count (0.6). A four-marker model was developed and discriminated HCC from liver cirrhosis with an AUC of 0.97. The best cut-off was 1.28, at which sensitivity and specificity were 90% and 85%, respectively. For small tumor (< 2 cm), the model had an AUC of 0.95 compared to AFP (0.72). Also, the model achieved perfect performance with AUC of 0.93, 0.94, and 0.95 for BCLC (0-A), CLIP (0-1), and Okuda (stage I), respectively, compared to AFP (AUC of 0.71, 0.69, and 0.67, respectively). CONCLUSIONS: The four markers may serve as a diagnostic model for HCC early stages and help overcome AFP poor sensitivity. |
format | Online Article Text |
id | pubmed-8556404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85564042021-11-10 A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus Omran, Mohamed M. Mosaad, Sara Emran, Tarek M. Eltaweel, Fathy M. Farid, Khaled J Genet Eng Biotechnol Research BACKGROUND: The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. This work aimed to assess interleukin (IL-6) and insulin-like growth factor 2 (IGF 2) as possible HCC markers in comparison to AFP in patients with and without HCC. RESULTS: ROC analysis showed that IGF2 had the highest area under the curve (AUC) for discriminating HCC from liver cirrhosis (0.86), followed by IL6 (0.82), AFP (0.72), and platelet count (0.6). A four-marker model was developed and discriminated HCC from liver cirrhosis with an AUC of 0.97. The best cut-off was 1.28, at which sensitivity and specificity were 90% and 85%, respectively. For small tumor (< 2 cm), the model had an AUC of 0.95 compared to AFP (0.72). Also, the model achieved perfect performance with AUC of 0.93, 0.94, and 0.95 for BCLC (0-A), CLIP (0-1), and Okuda (stage I), respectively, compared to AFP (AUC of 0.71, 0.69, and 0.67, respectively). CONCLUSIONS: The four markers may serve as a diagnostic model for HCC early stages and help overcome AFP poor sensitivity. Springer Berlin Heidelberg 2021-10-29 /pmc/articles/PMC8556404/ /pubmed/34714420 http://dx.doi.org/10.1186/s43141-021-00262-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Omran, Mohamed M. Mosaad, Sara Emran, Tarek M. Eltaweel, Fathy M. Farid, Khaled A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title | A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title_full | A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title_fullStr | A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title_full_unstemmed | A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title_short | A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus |
title_sort | novel model based on interleukin 6 and insulin-like growth factor ii for detection of hepatocellular carcinoma associated with hepatitis c virus |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556404/ https://www.ncbi.nlm.nih.gov/pubmed/34714420 http://dx.doi.org/10.1186/s43141-021-00262-8 |
work_keys_str_mv | AT omranmohamedm anovelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT mosaadsara anovelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT emrantarekm anovelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT eltaweelfathym anovelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT faridkhaled anovelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT omranmohamedm novelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT mosaadsara novelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT emrantarekm novelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT eltaweelfathym novelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus AT faridkhaled novelmodelbasedoninterleukin6andinsulinlikegrowthfactoriifordetectionofhepatocellularcarcinomaassociatedwithhepatitiscvirus |